ALVAIZ (eltrombopag tablets) is an FDA-approved prescription medication by Teva Pharmaceuticals used to treat low blood platelet counts (thrombocytopenia).
ALVAIZ (eltrombopag tablets) is an oral thrombopoietin receptor agonist indicated for the treatment of thrombocytopenia in certain adult and pediatric patients.
Manufactured by Teva Pharmaceuticals, it is commonly prescribed for patients with persistent or chronic immune thrombocytopenia (ITP), chronic hepatitis C-associated thrombocytopenia, or severe aplastic anemia. Our repository includes patient medication guides, FDA prescribing information, and detailed dosage instructions to help patients and healthcare providers safely manage ALVAIZ therapy.
Azken eskuliburuak hemendik: manuals+ marka honetarako prestatua.
Marka honen eskuliburuei, erregistroari eta laguntzari buruzko ohiko galderak.
ALVAIZ is an FDA-approved medication used to treat low blood platelet counts (thrombocytopenia) in patients with persistent or chronic immune thrombocytopenia (ITP), chronic hepatitis C, or severe aplastic anemia.
ALVAIZ should be taken without a meal or with a meal low in calcium (50 mg). It is important to follow the specific dosage instructions provided by a healthcare provider.
Common adverse reactions include anemia, nausea, pyrexia, increased alanine aminotransferase, cough, fatigue, headache, and diarrhea.
No, lactating women are advised not to breastfeed during treatment with ALVAIZ.